Zhu et al. (2014) found that DR5 activation mitigated intestinal inflammation and damage in a mouse model of IBD. In vitro, DR5 agonists reduced the release of inflammatory mediators by inducing apoptosis in inflammatory and intestinal epithelial cells (Kuo et al., 2019). This evidence concerns the gene TNFRSF10B and inflammatory bowel disease.